BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Edge Therapeutics, a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies for acute, life-threatening neurological conditions, today announced that it has initiated patient enrollment in the second cohort of the NEWTON study, a multicenter, randomized, controlled, open-label, Phase 1/2 clinical trial of the company’s lead product candidate, EG-1962.
Help employers find you! Check out all the jobs and post your resume.
